Supplemental Table 1. Demographic information

		Huntington's D	isease Carriers	4	Healthy Controls				
	HD1 ^B HD2		HD3	HC1	HC2	HC3	HC4		
	Premanifest	Premanifest	Symptomatic	Premanifest					
N	12	9	5	21	12	20	12	18	
Age	46.8(11.0) ^C	38.5(12.3)	53.8(6.3)	40.3(6.8)	40.8(14.7)	47.7(13.5)	42.5(15.6)	39.8(15.1)	
CAG repeat	41.6(1.7)	41.4(1.4)	N/A	42.9(2.3)	-	-	-	-	
length									
Predicted YTO	10.3(8.6)	13.8(5.9)	N/A	11.7(6.5)	-	-	-	-	
Imaging	FDG PET	FDG PET	FDG PET	FDG PET	FDG PET	FDG PET	RAC PET	MRI	
	RAC PET			MRI					
	MRI								

^ASee text for definitions of the Huntington's disease (HD1-HD3) and healthy control (HC1-HC4) groups.

HD=Huntington's Disease Carrier Groups, HC=Healthy Control Groups, YTO=Years-to-onset.

^BBaseline data.

^CValues are presented as mean (SD).

Supplemental Table 2. UHDRS motor ratings and measurements of caudate/putamen D_2 binding and tissue volume

		HD1 (longitu	dinal cohort)		HD2	НС
	Baseline	1.5 years	4 years	7 years	(symptomatic)	
UHDRS (motor)	(n=12)	(n=12)	(n=10)	(n=9)	(n=5)	
Phenoconverters	23.8 (9.8) ^A	22.7 (11.0)	27.0 (10.9)	33.3 (9.2)		
Non-phenoconverters	2.5 (2.5)	5.5 (6.7)	2.2 (1.0)	2.0 (1.6)	42.8 (4.4)	N/A
Total	9.6 (11.8)	10.2 (10.9)	12.1 (14.3)	15.9 (17.4)		
Striatal D ₂ Binding		<u> </u>	l			
Caudate						
Phenoconverters	0.92 (0.42)	0.95 (0.22)	0.79 (0.28)	0.71 (0.19)		
Non-phenoconverters	1.50 (0.27)	1.39 (0.30)	1.31 (0.38)	1.28 (0.04)	0.72 (0.20)	2.09 (0.43)
Total	1.34 (0.40)	1.23 (0.34)	1.10 (0.43)	1.06 (0.32)		
Putamen						
Phenoconverters	1.01 (0.25)	1.02 (0.11)	0.87 (0.13)	0.79 (0.11)		
Non-phenoconverters	1.50 (0.29)	1.36 (0.28)	1.29 (0.27)	1.26 (0.08)	0.80 (0.22)	2.07(0.39)
Total	1.37 (0.35)	1.24 (0.28)	1.12 (0.30)	1.08 (0.26)		
Striatal Tissue Volume						
Caudate						
Phenoconverters	0.64 (0.29) ^B	0.59 (0.29)	0.57 (0.30)	0.45 (0.16)	0.50 (0.40)	4.00(0.05)
Non-phenoconverters	0.86 (0.18)	0.82 (0.19)	0.84 (0.20)	0.78 (0.12)	0.56 (0.12)	1.00(0.05)

Total	0.79 (0.24)	0.74 (0.24)	0.74 (0.26)	0.63 (0.22)		
Putamen		I	l	l		
Phenoconverters	0.68 (0.17)	0.68 (0.19)	0.64 (0.18)	0.56 (0.17)		
Non-phenoconverters	0.98 (0.22)	0.90 (0.22)	0.87 (0.20)	0.87 (0.11)	0.60 (0.14)	1.00 (0.05)
Total	0.88 (0.24)	0.82 (0.23)	0.78 (0.22)	0.73 (0.21)		

AMean (SD).

BPercent of the normal mean
UHDRS=Unified Huntington's Disease Rating Scale; HD=Huntington's disease; HC=healthy control.

Supplemental Table 3. Regions with significant loadings on the HD volume-loss progression pattern

	Coo	rdinate	es ^A	
Brain region	X	у	Z	Zmax ^B
Declining Activity				
Putamen, right	24	8	0	4.53***
left	-22	6	6	4.03***
Caudate, right	14	4	18	3.47***
left	-10	12	10	2.92**
Posterior occipital (BA 18)	2	-92	-14	3.35***
Supplementary motor area (BA 6)	4	28	54	3.14**
Premotor cortex (BA 6)	-24	-8	62	2.96**
Superior temporal (BA 38), right	36	14	-18	2.46*
left	-42	12	-10	2.93**
Insula	-44	-4	0	2.52*
Prefrontal cortex (BA 9), right	2	50	34	2.65**
(BA 10)	0	54	6	2.58*
Prefrontal cortex (BA 9), left	-50	12	36	2.88**
Precuneus (BA 7)	6	-80	38	2.51*


^AMontreal Neurological Institute (MNI) standard space (1).

BA=Brodmann Area.

^BRegions with significant loadings on the metabolic progression pattern (see text). *Z*-values at peak voxel are given for each region (*p<0.05, **p<0.01, ***p<0.001). Additionally, the weights on each of the regions were found to be reliable on bootstrap estimation (p<0.001; 1,000 iterations).

Supplemental Figures


Supplemental Figure 1



Supplemental Figure 1. Cross-sectional correlations of metabolic progression pattern expression with the predicted years-to-onset


In the premanifest HD1 cohort, the expression of the metabolic progression pattern correlated with the predicted years-to-onset (p<0.05; Pearson's correlations) at baseline ($\bf A$) and at the three follow-up time points ($\bf B$ - $\bf D$). Correlations of similar magnitude between these variables were evident in the test (p=0.06) and retest (p<0.03) scans of the premanifest HD2 subjects ($\bf E$, $\bf F$), and in the baseline (p<0.02) and follow-up (p<0.03) scans of the premanifest HD3 cohort ($\bf G$, $\bf H$). [Post-phenoconversion values are represented by filled symbols].

Supplemental Figure 2



Supplemental Figure 2. Changes in UHDRS motor ratings vs. years-to-onset

Unified Huntington's disease rating scale (UHDRS) motor ratings plotted against years-to-onset values for the members of the initially premanifest HD1 cohort (see text). Predicted years-to-onset values (2) were used for the non-phenoconverters (*blue*). The time until actual clinical diagnosis was used for the four members of this cohort who subsequently phenoconverted (*red*), and for the five early symptomatic members (*yellow*) of the HD2 prospective testing cohort (see text).



Supplemental Figure 3. Changes in the expression of the HD metabolic progression pattern, caudate D_2 -receptor binding and tissue volume as a function of the disease burden index

As an alternative to using an empirically predicted years-to-onset measure (2), we repeated the IGM analyses using the disease burden index (3). The results were very similar to those reported using the former measure.

- (A) Pattern expression in the longitudinal HD1 cohort increased linearly with increasing disease burden index (p<0.0001; IGM).
- (**B**) Caudate D_2 -receptor binding values measured using [11 C]-raclopride PET exhibited a linear decline with increasing disease burden index (p<0.01; IGM).
- (C) Caudate tissue volume measurements acquired with volumetric MRI also exhibited a linear decrease with disease burden (p<0.0001; IGM).

[Disease burden=(CAG length -35.5)×age. Red and blue lines denote the phenoconverters and non-phenoconverters. Solid line and broken curves depict the best fitted line and the 95% CI. Dotted lines represent 2 SD above and below the normal mean. In (**B**) and (**C**), individual values represented percent of the normal mean (*broken line*)].

(**D**) The rate of increase in the HD metabolic pattern expression (*red*) was greater (p<0.0001, IGM) than the rates of decline measured for caudate D₂-receptor binding (*light blue*) and tissue volume (*dark blue*). [Values for caudate D₂-receptor binding and tissue volume were flipped and analyzed as increasing mirror lines (*dotted lines*). Y-axis represents the standard z-scale. Horizontal dotted line represents the normal mean (zero) for each parameter. Vertical dotted line represents the time of phenoconversion (i.e., years-to-onset was zero)].

Supplemental References

- 1. Collins, DL, Neelin, P, Peters, TM, and Evans, AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. *J Comput Assist Tomogr.* 1994;18:192-205.
- 2. Langbehn, DR, Brinkman, RR, Falush, D, Paulsen, JS, and Hayden, MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. *Clin Genet*. 2004;65:267-277.
- 3. Tabrizi, SJ, Reilmann, R, Roos, RA, Durr, A, Leavitt, B, Owen, G, Jones, R, Johnson, H, Craufurd, D, Hicks, SL, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. *Lancet Neurol.* 2012;11:42-53.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Dhawan 1



Section 1.	dentifying Inform	ation	
1. Given Name (First Vijay	Name)	2. Surname (Last Name) Dhawan	3. Date 11-June-2013
4. Are you the corres	sponding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Network	c as a Progression Bio	marker of Premanifest Hu	ntington's Disease
6. Manuscript Identii	fying Number (if you kn	ow it)	
			_
Section 2.	he Work Under Co	onsideration for Public	cation
any aspect of the sub statistical analysis, et	mitted work (including	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.
of compensation) v clicking the "Add +	with entities as descri	bed in the instructions. Use port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4.	ntellectual Proper	ty Patents & Copyrig	yhts
Do you have any pa	atents, whether planr	ned, pending or issued, br	oadly relevant to the work? Yes V No

Dhawan 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Dhawan has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Dhawan 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

expert testimony, employment, or other affiliations



Section 1. Identifying Inform	ation				
Given Name (First Name) David	2. Surnam Eidelberg	ne (Last Nai	me)		3. Date 07-June-2013
4. Are you the corresponding author?	✓ Yes	No			
5. Manuscript Title Metabolic Network as a Progression Bio	marker of I	Premanife	st Huntington's [Disease	
6. Manuscript Identifying Number (if you kn 69411	ow it)				
Section 2. The Work Under Co	nsiderat	ion for P	ublication		
Did you or your institution at any time receinany aspect of the submitted work (including statistical analysis, etc.)?	but not lim				
Are there any relevant conflicts of intere			No		
If yes, please fill out the appropriate info Excess rows can be removed by pressing			u have more tha	n one entit	ty press the "ADD" button to add a row.
Name of Institution/Company		Personal Fees	Non-Financial Support?	Other?	Comments
National Institutes of Health (NINDS)	✓				
National Institutes of Health (NIBIB)	✓				
CHDI Foundation, Inc.	√				
Section 3. Relevant financial a	activities	outside	the submitted	work.	
Place a check in the appropriate boxes in of compensation) with entities as descri					
clicking the "Add +" box. You should rep					
Are there any relevant conflicts of intere			No		
If yes, please fill out the appropriate info	rmation be	elow.			
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Pfizer, Inc.		V			Consultant fees.



Name of Entity	Gra	ant•	rsonal ees?	Non-Financial Support?	Other?	Comi	ments	
Michael J. Fox Foundation for Parkinson Research	on's [✓			Scientif honora	ic advisory board and ria.	
Bachmann-Strauss Dystonia and Parki Foundation	nson [✓	✓			Scientif honora	ic advisory board and ria.	
High Q Foundation		✓						
Dana Foundation		✓						
Thomas Hartman Foundation for Park Research, Inc.	inson's		✓			Scientif	ic advisor.	
Do you have any patents, wheth If yes, please fill out the appropr Excess rows can be removed by	ner planned, _l iate informat	pending	or issued w. If you	d, broadly releva			Yes No the "ADD" button to add a ro	W.
Patent?	Pending?	Issued?	License	ed? Royalties?	License	e?	Comments	
NO. 5,632,276		√			David Eide (coinvento	_	No financial gain.	
NO. 5,873,823		✓			David Eide (coinvento	_	No financial gain.	
Are there other relationships or potentially influencing, what yo Yes, the following relationships/cond	activities tha u wrote in th ips/condition	t readers e submit ns/circum	could p ted worl	k? are present (exp	olain belc	w):		



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Eidelberg reports grants from National Institutes of Health (NINDS), grants from National Institutes of Health (NIBIB), grants from CHDI Foundation, Inc., during the conduct of the study; personal fees from Pfizer, Inc., personal fees from Michael J. Fox Foundation for Parkinson's Research, grants and personal fees from Bachmann-Strauss Dystonia and Parkinson Foundation, grants from High Q Foundation, grants from Dana Foundation, personal fees from Thomas Hartman Foundation for Parkinson's Research, Inc., outside the submitted work; In addition, Dr. Eidelberg has a patent NO. 5,632,276 issued to David Eidelberg (coinventor), and a patent NO. 5,873,823 issued to David Eidelberg (coinventor).

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not



Section 1.	Identifying Inform	ation								
1. Given Name (Fir Andrew	rst Name)	2. Surnar Feigin	ne (Last Nar	ne)	3. Date 11-June-2013					
4. Are you the cor	responding author?	Yes	✓ No	-	Corresponding Author's Name Dr. David Eidelberg					
5. Manuscript Title Metabolic Netwo	e ork as a Progression Bio	marker of	Premanife	st Huntington's D)isease					
6. Manuscript Ider 69411	ntifying Number (if you kn	ow it)								
Section 2.	The Work Under Co	nsidera	tion for P	ublication						
any aspect of the si statistical analysis,	ubmitted work (including	but not lim		its, data monitoring	-	ent, commercial, private foundation, oudy design, manuscript preparation,	etc.) for			
Section 3.	Relevant financial a	activities	outside	the submitted	work.					
of compensation clicking the "Add Are there any rele) with entities as descril	oed in the ort relationst?	instruction onships tha Yes	ns. Use one line fo	or each er	cial relationships (regardless of am ntity; add as many lines as you ned e 36 months prior to publicatio	ed by			
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
Allergan, Inc.			√			Speaker fees.				
TEVA Pharmaceutical	Industries Ltd.		√			Speaker fees.				
lpsen			✓			Consultant fees.				
Lundbeck			✓			Consultant fees.				
Merz Pharmaceutical	S		✓			Consultant fees.				
National Institutes of	Health (NINDS)	✓								
Huntington's Disease	Society of America	✓								



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments	
Michael J. Fox Foundation for Parkinson's Research	✓				
Medivation, Inc.	✓				
Novartis	✓				
Phytopharm	✓				
Section 4. Intellectual Propert	y Patents & Cop	pyrights			
Do you have any patents, whether plann	ed, pending or issue	d, broadly releva	nt to the	work? Yes 🗸 No	
Section 5. Relationships not c	overed above				
Are there other relationships or activities potentially influencing, what you wrote i			nfluenced	d, or that give the appearance of	
Yes, the following relationships/cond	litions/circumstance	s are present (ext	olain belo	w):	
✓ No other relationships/conditions/cir					
At the time of manuscript acceptance, jo On occasion, journals may ask authors to				· ·	ts.
Section 6. Disclosure Statemen					
Disclosure Stateme	nt				
Based on the above disclosures, this form below.	ા will automatically દ્	generate a disclos	sure state	ment, which will appear in the box	
Dr. Feigin reports personal fees from Alle from Ipsen, personal fees from Lundbecl Health (NINDS), grants from Huntington Research, grants from Medivation, Inc., g	k, personal fees from 's Disease Society of	Merz Pharmace America, grants f	uticals, gra from Mich	ants from National Institutes of nael J. Fox Foundation for Parkinson's	



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Guttman 1



Section 1. Identifying Inform	ation					
1. Given Name (First Name) Mark	2. Surname (Last Name) Guttman		3. Date 11-June-2013			
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg				
5. Manuscript Title Metabolic Network as a Progression Bio	marker of Premanifest Hu	ntington's Disease				
6. Manuscript Identifying Number (if you kn 69411	ow it)	_				
Continue						
Section 2. The Work Under Co	onsideration for Public	cation				
Did you or your institution at any time recei- any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da					
Section 3. Relevant financial a	activities outside the s	submitted work.				
Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box. You should rep	bed in the instructions. Us	se one line for each e	ntity; add as many lines as you need by			
Are there any relevant conflicts of intere	st? ✓ Yes No					
If yes, please fill out the appropriate info	rmation below.					
Name of Entity	Grant	n-Financial Other?	Comments			
NeuroDerm			Equity.			
Merck			Research funding for clinical trial in Parkinson's disease.			
Section 4. Intellectual Proper	ty Patents & Copyric	ghts				
Do you have any patents, whether plann			work? ☐ Yes ✓ No			

Guttman 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Guttman reports other from NeuroDerm, grants from Merck, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Guttman 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Habeck 1



Section 1. Identifying Inform	nation	
Given Name (First Name) Christian	2. Surname (Last Name) Habeck	3. Date 11-June-2013
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Network as a Progression Bio	omarker of Premanifest Hu	ntington's Disease
6. Manuscript Identifying Number (if you ki	now it)	
Section 2. The Work Under C	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ata monitoring board, study design, manuscript preparation,
Section 3. Polywort financial		
Relevant financial	activities outside the	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Prope	rty Patents & Copyric	ghts
Do you have any patents, whether plan		

Habeck 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Habeck has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Habeck 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Leenders 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Klaus	2. Surname (Last Name) Leenders	3. Date 11-June-2013
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Network as a Progression Bio	omarker of Premanifest Hu	ntington's Disease
6. Manuscript Identifying Number (if you kr	now it)	
		_
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by the present during the 36 months prior to publication.
Section 4. Intellectual Proper		de.
Intellectual Proper	rty Patents & Copyric	ints ———
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Leenders 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Leenders has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Leenders 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

1 Ma



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Yilong	2. Surname (Last Name) Ma	3. Date 11-June-2013
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Network as a Progression Bio	omarker of Premanifest Hu	ntington's Disease
6. Manuscript Identifying Number (if you kr	now it)	
Section 2. The Work Under Co	onsideration for Public	cation
	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descri	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Proper	str. Dataute Commi	ulata .
intellectual Proper	rty Patents & Copyric	ints ———
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Ma 2



Section 5.	
R	elationships not covered above
	tionships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?
Yes, the following	ng relationships/conditions/circumstances are present (explain below):
✓ No other relation	nships/conditions/circumstances that present a potential conflict of interest
	iscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements Ils may ask authors to disclose further information about reported relationships.
Section 6. D	isclosure Statement
Based on the above below.	disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Ma has nothing	to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Ma 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Paulsen 1



Section 1.	Identifying Inform	nation	
1. Given Name (Fi	rst Name)	2. Surname (Last Name) Paulsen	3. Date 11-June-2013
4. Are you the cor	responding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Netwo		marker of Premanifest Hu	ntington's Disease
6. Manuscript Ider 69411	ntifying Number (if you kr	now it)	
Section 2.	The Work Under Co	onsideration for Public	cation
any aspect of the s statistical analysis,	ubmitted work (including	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.
of compensation clicking the "Add) with entities as descri	bed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4.	Intellectual Proper	ty Patents & Copyric	ghts
Do you have any	patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Paulsen 2



Section 5. Relationships not covered above
helationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disalogues Statement
Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Paulsen has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Paulsen 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Tang 1



Section 1.	Identifying Inform	ation	
1. Given Name (Firs Chris	t Name)	2. Surname (Last Name) Tang	3. Date 11-June-2013
4. Are you the corre	esponding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Networ	k as a Progression Bio	marker of Premanifest Hu	ntington's Disease
6. Manuscript Ident 69411	ifying Number (if you kn	ow it)	
Section 2.	The Work Under Co	onsideration for Public	cation
any aspect of the su statistical analysis, e	bmitted work (including	but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ita monitoring board, study design, manuscript preparation,
Section 3.	Relevant financial	activities outside the s	submitted work.
of compensation) clicking the "Add -	with entities as descri	bed in the instructions. Use port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4.	Intellectual Proper	ty Patents & Copyri	ghts
Do you have any p	patents, whether plans	ned, pending or issued, br	oadly relevant to the work? Yes V No

Tang 2



Section 5.	
Rection 3.	elationships not covered above
	ionships or activities that readers could perceive to have influenced, or that give the appearance of ng, what you wrote in the submitted work?
Yes, the following	g relationships/conditions/circumstances are present (explain below):
✓ No other relation	ships/conditions/circumstances that present a potential conflict of interest
	script acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements s may ask authors to disclose further information about reported relationships.
Section 6. Di	sclosure Statement
Based on the above below.	disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Tang has nothing	g to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Tang 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Teune 1



Section 1. Identifying Inform	nation	
1. Given Name (First Name) Laura	2. Surname (Last Name) Teune	3. Date 11-June-2013
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg
5. Manuscript Title Metabolic Network as a Progression Bio	omarker of Premanifest Hu	ntington's Disease
6. Manuscript Identifying Number (if you k	now it)	
Section 2. The Work Under C	onsideration for Public	cation
	g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for ta monitoring board, study design, manuscript preparation,
Section 3. Relevant financial	activities outside the s	submitted work.
of compensation) with entities as descr	ibed in the instructions. Us port relationships that wer	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4. Intellectual Prope	rty Patents & Copyric	ghts
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No

Teune 2



Section 5. Relationships not sovered above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Teune has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Teune 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

1 van Oostrom



Section 1. Identifying Inform	nation		
Given Name (First Name) Joost	2. Surname (Last Name) van Oostrom	3. Date 11-June-2013	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author's Name Dr. David Eidelberg	
5. Manuscript Title Metabolic Network as a Progression Bio	omarker of Premanifest Hui	ntington's Disease	
6. Manuscript Identifying Number (if you kr	now it)		
Section 2. The Work Under Consideration for Publication			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes Yes			
Section 3. Relevant financial	activities outside the s	ubmitted work.	
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes Vo			
Section 4. Intellectual Proper	rty Patents & Copyrig	hts	
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	

van Oostrom 2



Section 5. Polationships not severed above
Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. van Oostrom has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

van Oostrom 3